Tiziana Life Sciences (TILS)

 

Latest News

Tiziana Life Sciences completes share placement

Tiziana Life Sciences said it raised 100,000 from a share issue, at an issue price of 150p per share. At 8:26am: (LON:TILS) Tiz...

Tiziana Life Sciences places news shares

Tiziana Life Sciences has raised 150,000 via a share issue at 150p per share Each placing share had a warrant attached entitl...

Placing

RNS Number: 9305B Tiziana Life Sciences PLC 16 January 2018 Tiziana Life Sciences plc (" Tiziana " or the " Company ") Placing to raise 150,000 and issue of equity London, January 16, 2018 - Tiziana Life Sciences plc (AIM: TILS), a clinical stage biotechnology company developing targeted drugs for cancer and autoimmune diseases, today announces that it has raised...

Placing and Issue of Equity

RNS Number: 4366Z Tiziana Life Sciences PLC 15 December 2017 Tiziana Life Sciences plc (" Tiziana " or the " Company ") Placing to raise 200,000 and issue of equity London, December 15, 2017 - Tiziana Life Sciences plc (AIM: TILS), a clinical stage biotechnology company developing targeted drugs for cancer and autoimmune diseases, today announces that it has r...

All News

DateHeadlineSource
22-01-18Tiziana Life Sciences completes share placementStockMarketWire
16-01-18Tiziana Life Sciences places news sharesStockMarketWire
16-01-18PlacingRNS
15-12-17Placing and Issue of EquityRNS
08-12-17Tiziana Life Sciences says cancer drug well-toleratedStockMarketWire
08-12-17Milciclib Phase 2a Trial UpdateRNS
27-11-17Tiziana Life Sciences issues sharesStockMarketWire
27-11-17PlacingRNS
23-11-17Tiziana rare cancer drug meets endpointsStockMarketWire
23-11-17Phase II Clinical Trial UpdateRNS
20-11-17Tiziana Life Sciences completes share issueStockMarketWire
20-11-17SubscriptionRNS
29-09-17Interim Results for Six Months Ended 30 June 2017RNS
06-09-17Tiziana says development of oral formulation of foralumab to be used in clinical studiesStockMarketWire
06-09-17A Proprietary Oral Formulation of ForalumabRNS
31-08-17Grant of options - Director's dealingRNS
16-08-17Tiziana converts loan notes to sharesStockMarketWire
16-08-17Conversion of outstanding loan notesRNS
28-07-17Publication of Research Article on ForalumabRNS
19-07-17Tiziana enrols first patient in Phase IIa clinical trialStockMarketWire
19-07-17Initiation of a Phase IIa Clinical TrialRNS
12-07-17Proposed changes to CLNs and Warrant TermsRNS
29-06-17Result of AGMRNS
12-06-17Appointment of Dr Kunwar Shailubhai as CEORNS
08-06-17NOTIFICATION OF MAJOR INTEREST IN SHARESRNS
08-06-17Bcl-3 pre-clinical update and Director's dealingRNS
01-06-172016 Annual Report and Accounts and notice of AGMRNS
23-05-17Financial Results for Year Ended 31 December 2016RNS
24-04-17Broker Forecast - Beaufort Securities issues a broker note on Tiziana Life Sciences Plc Ord 3pStockMarketWire
24-04-17TILS confirms Phase II clinical trial protocol for Milciclib StockMarketWire
24-04-17Announces Approval of a Phase II Clinical TrialRNS
21-04-17Announces Publication of Milciclib Clinical TrialRNS
24-03-17Tiziana Life Sciences notes exercise of warrantsStockMarketWire
24-03-17Exercise of Warrants & Issue of EquityRNS
14-03-17Arun Sanyal appointed to Scientific Advisory BoardRNS
16-01-17Warrant Expiry - ReminderRNS
03-01-17Tiziana Life Sciences in-licences NI-1201StockMarketWire
03-01-17Tiziana Life Sciences in-licenses NI-1201RNS
16-11-16Tiziana announces new data with ForalumabStockMarketWire
16-11-16New Data with ForalumabRNS

RSS feeds

  • Editorial news feed for LSE:TILS Editorial
  • Regulatory news feed for LSE:TILS Regulatory

Join interactive investor

  • £22.50 fixed quarterly charge includes £22.50 in trading credits
  • £10 per trade or £6 for frequent traders
  • No % platform fees
  • £1 per trade for regular investment or dividend reinvestment

Open an account